Early Opportunities for Optimized Polycythemia Vera Care: From Understanding Clinical Manifestations to Evaluating Diagnosis Strategies

 

ASH 2022 Conference Coverage
M

MAJIC-PV Trial: Ruxolitinib vs. Best Available Therapy for PV Intolerant or Resistant to Hydroxycarbamide in a Randomized Trial

By ASH 2022 Conference Coverage FEATURING Mary Frances McMullin
By ASH 2022 Conference Coverage FEATURING Mary Frances McMullin
1,062 views
February 1, 2023
0 Comments
Login to view comments. Click here to Login
Early Opportunities for Optimized Polycythemia Vera Care: From Understanding Clinical Manifestations to Evaluating Diagnosis Strategies
23:35
University of Colorado Division of Hematology

2024 Updates in PV/ET

Feat. B. McMahon
09:27
ASH 2022 Conference Coverage

MAJIC-PV Trial: Ruxolitinib vs. Best Available Therapy for PV Intole…

Feat. M. McMullin
10:49
Monia Marchetti

Using Cytoreductive Therapy to Prevent Cardiovascular Events in Pati…

08:18
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Treatment Strategies for Hematocrit Control…

Feat. A. Zhou
16:25
Northwestern Medicine Oncology and Hematology

Diagnosis and Goals of Therapy in PV

Feat. B. Stein